Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia

• ClinicalTrials.gov Identifier: NCT01108770
• Recruitment Status: Completed
• First Posted: April 22, 2010
• Last Update Posted: August 21, 2012
• Sponsor: Edimer Pharmaceuticals
• Information provided by (Responsible Party): Edimer Pharmaceuticals

Study Description

Brief Summary:

To characterize skin properties in male subjects with HED

Condition or disease
Ectodermal Dysplasia

Detailed Description:

This study is designed to obtain information from male subjects with HED and unaffected male control subjects. The study will consist of the standardized collection of data from HED medical history questionnaires and non-invasive tests. A subset of subjects will undergo genetic testing. All data will be collected from families attending the 2010 NFED Family Conference, July 22-24, 2010, in Colorado Springs, CO.

Since HED is a rare disease, it is difficult to obtain reliable data on a sufficient number of subjects in any one region. The NFED Family Conference is a location where families affected with HED come together, and therefore, presents an ideal location to obtain data needed to design future studies. As the procedures are non-invasive and are designed to take a relatively short period of time, subjects can participate in this study while attending the NFED Family Conference.

Study Design

• Study Type: Observational
• Actual Enrollment: 62 participants
• Official Title: Evaluation of Phenotypic and Genetic Properties in Male Subjects With Hypohidrotic Ectodermal Dysplasia and Their Family Members
• Study Start Date: July 2010
• Actual Primary Completion Date: July 2010
• Actual Study Completion Date: October 2010

Groups and Cohorts

Group/Cohort
HED affected males
Unaffected male controls

Outcome Measures

Primary Outcome Measures :

1. Characterization of skin properties in HED affected male subjects compared with healthy controls [ Time Frame: Two assessments conducted once during study day. ]
   The primary objective of this descriptive study is to use skin assessment techniques to characterize skin properties in male subjects affected by HED compared with healthy controls including determination of the number of sweat glands and the rate of sweating.

Secondary Outcome Measures :

1. Collecting demographic information and clinical status in male subjects affected by HED using a medical questionnaire. [ Time Frame: Collected once during study day. ]
2. Testing for the presence of ectodysplasin A (EDA) gene mutations in a subset of subjects enrolled in this study. [ Time Frame: Collected once during study day. ]

Biospecimen Retention:   Samples With DNA

Blood samples

Eligibility Criteria

• Ages Eligible for Study: 1 Year and older (Child, Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes
• Sampling Method: Non-Probability Sample

Study Population

Male subjects with HED or unaffected controls

Criteria

Inclusion Criteria:

1. Registered and attending the 2010 NFED Family Conference;
2. One year of age or greater;

3. Conform to one of the following requirements for providing informed consent:

   • if more than 18 years of age, subjects must provide signed informed consent;
   • if less than 18 years of age and it is determined that the subject is capable of providing assent, both the assent of the subject and consent of the parent(s) or guardian of that subject must be granted. Under this condition, both parents of the subject should give their permission, unless 1 parent is deceased, unknown, incompetent, or not available;
   • if the subject is incapable of providing assent, the consent of the parent(s) or guardian of the subject must be granted. Under this condition, both parents should give their consent, unless 1 parent is deceased, unknown, incompetent, or not available.

4. Subjects must meet one of the following criteria:

   • Male subjects of original gender with the clinical characteristics of HED, including at least a history of decreased sweating and either abnormal teeth (fewer permanent teeth, teeth are smaller than average and often have conical crowns), and/or sparseness of scalp and body hair;
   • Healthy male controls, i.e. either unaffected male family members or unaffected male volunteers.

Exclusion Criteria:

1. Known hypersensitivity to pilocarpine or pilocarpine-like muscarinic agonists.
2. Presence of pacemakers.
3. Subjects who are not able or are not willing to comply with the procedures of this protocol.
4. Subjects with any major medical problem that will prevent them from participating in this study.

Contacts and Locations

Locations

United States, Colorado

Cheyenne Mountain Resort

Colorado Springs, Colorado, United States, 80906

Sponsors and Collaborators

Edimer Pharmaceuticals

Investigators

• Principal Investigator: Dorothy K Grange, MD; Washington University School of Medicine

More Information

• Responsible Party: Edimer Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT01108770 History of Changes
• Other Study ID Numbers: ECP-001
• First Posted: April 22, 2010
• Last Update Posted: August 21, 2012
• Last Verified: August 2012

Keywords provided by Edimer Pharmaceuticals:

HED; XLHED; Hypohidrotic Ectodermal Dysplasia

Additional relevant MeSH terms:

Ectodermal Dysplasia; Ectodermal Dysplasia 1, Anhidrotic; Hyperplasia; Pathologic Processes; Abnormalities, Multiple; Congenital Abnormalities; Skin Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin Diseases; Genetic Diseases, X-Linked